Introduction
What treatments are used for macular degeneration? The answer depends on whether the condition is the dry form or the wet form, because each reflects a different biological process in the retina. Dry age-related macular degeneration is managed mainly with nutritional therapy, risk-factor control, and monitoring, while wet age-related macular degeneration is treated with medications that block abnormal blood vessel growth and leakage. In some cases, laser-based procedures or implanted devices are used when standard therapy is not sufficient. Across all approaches, treatment is aimed at slowing retinal damage, limiting fluid and bleeding, preserving central vision, and, when possible, restoring more normal function in the macula.
Understanding the Treatment Goals
The macula is the central part of the retina responsible for detailed vision, reading, and facial recognition. Macular degeneration damages this region through different mechanisms depending on the subtype. In dry macular degeneration, retinal cells, supporting tissue, and the retinal pigment epithelium gradually degenerate, often with accumulation of drusen, which are deposits beneath the retina. In wet macular degeneration, fragile new blood vessels grow from the choroid into the retina, a process called choroidal neovascularization. These vessels leak fluid, blood, and proteins, leading to swelling, scarring, and rapid loss of central vision.
Treatment goals follow from these mechanisms. For dry disease, the main objective is to slow structural deterioration and reduce the risk of progression to advanced disease. For wet disease, the goal is to suppress abnormal vessel growth, reduce leakage and edema, and prevent irreversible scarring in the macula. In both forms, treatment also seeks to preserve remaining visual function and reduce complications that limit daily visual tasks. Because damage to macular tissue is often permanent once advanced, treatment focuses more on control than cure.
Common Medical Treatments
For dry macular degeneration, the most established medical approach is antioxidant and mineral supplementation in selected patients with intermediate disease or advanced disease in one eye. This is based on large clinical studies showing benefit from specific nutrient combinations, often referred to as AREDS or AREDS2 formulations. These supplements typically include vitamin C, vitamin E, zinc, copper, and in later formulations lutein and zeaxanthin. Their biologic rationale is to reduce oxidative stress in the retina. The macula consumes large amounts of oxygen and is exposed to light, making it vulnerable to oxidative injury. Over time, reactive oxygen species can damage photoreceptors, the retinal pigment epithelium, and the underlying Bruch membrane. Antioxidants are intended to buffer this injury, while zinc supports retinal enzyme systems and may influence transport and metabolic stability in retinal tissue.
These supplements do not reverse existing atrophy, and they are not used to treat all forms of dry disease. Their role is preventive rather than restorative: they are used to slow progression in individuals at higher risk of advanced degeneration. In that sense, they target the biochemical environment that contributes to retinal cell loss rather than an acute lesion.
For wet macular degeneration, the most common and effective medical treatment is intravitreal anti-VEGF therapy. VEGF, or vascular endothelial growth factor, is a signaling protein that stimulates new blood vessel formation and increases vascular permeability. In wet macular degeneration, VEGF is overexpressed in response to ischemia, inflammation, and retinal stress. Anti-VEGF drugs, such as ranibizumab, aflibercept, brolucizumab, and bevacizumab, bind VEGF or block its activity. By interrupting this signal, they reduce formation of abnormal vessels and decrease leakage from existing ones.
This mechanism directly addresses the core pathology of wet disease. Leakage from abnormal vessels causes macular edema, which distorts the retinal layers and impairs photoreceptor signaling. Recurrent leakage can also trigger fibrovascular scar formation. Anti-VEGF therapy reduces fluid accumulation, helps flatten retinal swelling, and can stabilize or improve visual acuity when used before permanent scarring occurs. Because VEGF activity can recur, treatment often requires repeated dosing to maintain suppression of the angiogenic process.
In some cases, corticosteroids are used less commonly as adjunctive treatment, particularly when inflammation contributes to retinal swelling. Steroids suppress inflammatory signaling and reduce capillary permeability, but they are not standard first-line therapy for typical age-related wet macular degeneration because anti-VEGF agents are more targeted to the primary abnormal pathway. Their use reflects a broader principle in retinal disease management: treatment choice depends on whether vascular leakage is driven primarily by angiogenic signaling, inflammation, or both.
Procedures or Interventions
Several procedures are used when medication alone is not sufficient or when a specific structural problem is present. The most established intervention for wet macular degeneration is intravitreal injection, which delivers anti-VEGF medication directly into the vitreous cavity. This route is used because the eye is a compartment, and local delivery achieves high retinal drug levels while limiting systemic exposure. The injection does not itself repair retinal tissue, but it changes the biochemical environment around the macula by suppressing the VEGF-mediated vascular response.
Laser photocoagulation was used more commonly before anti-VEGF therapy became standard, and it still has a limited role in certain patterns of neovascularization. The laser creates thermal injury that seals leaking vessels. Its effect is mechanical and destructive rather than biologic: it closes abnormal vascular channels by heat-induced coagulation. Because it can damage nearby retina and create scotomas, it is reserved for carefully selected cases where the lesion is outside the central fovea or when the anatomy makes laser treatment feasible.
Photodynamic therapy is another less common procedure. It combines an intravenous light-sensitive drug with laser activation to close abnormal vessels selectively. After the drug accumulates in neovascular tissue, a low-energy laser triggers a reaction that damages the vascular endothelium and causes vessel closure. This intervention is more selective than thermal laser and was especially relevant before anti-VEGF agents became dominant. It is still used in some combined or atypical cases, such as certain polypoidal choroidal vasculopathy patterns.
For advanced dry macular degeneration with geographic atrophy, there has traditionally been no procedure that reverses tissue loss. However, emerging therapies, including complement pathway inhibitors, are being developed and in some regions have been approved for slowing geographic atrophy progression. These agents target the complement cascade, part of the innate immune system thought to contribute to chronic retinal inflammation and cell loss. By dampening this pathway, the goal is to slow expansion of atrophic lesions rather than restore already lost retina.
In late-stage disease, low-vision rehabilitation is often considered a functional intervention rather than a biologic treatment. It uses optical and environmental adaptations to improve the use of remaining peripheral or parafoveal vision. While it does not alter retinal pathology, it compensates for the loss of central macular function and helps maintain visual performance in daily tasks.
Supportive or Long-Term Management Approaches
Long-term management is important because macular degeneration is usually chronic and progressive. Regular retinal monitoring allows clinicians to detect conversion from dry to wet disease or progression of neovascular activity before extensive damage occurs. Imaging methods such as optical coherence tomography reveal fluid, retinal thickening, and atrophy by showing the layered structure of the retina in cross-section. Fundus photography and fluorescein angiography can identify drusen, pigment changes, and vascular leakage. These tools are not treatments themselves, but they guide timely intervention by revealing biologic activity in the tissue.
Lifestyle-related management strategies are used because systemic conditions influence the retinal environment. Smoking is one of the strongest modifiable risk factors for progression, likely because tobacco exposure increases oxidative stress and impairs choroidal circulation. Cardiovascular health also matters because the retina depends on adequate microvascular perfusion. Blood pressure and lipid control do not directly treat retinal lesions, but they influence the vascular and inflammatory milieu in which the disease evolves.
Dietary patterns may also play a supportive role, especially in relation to antioxidant intake and omega-3 fatty acids, although dietary measures are less predictable than structured supplementation in high-risk dry disease. These approaches are best understood as ways of modifying the biochemical stress placed on retinal cells rather than as direct therapies for existing degeneration.
Ongoing follow-up is central to management because disease activity can change over time. In wet degeneration, repeated anti-VEGF treatment is adjusted according to retinal fluid and visual response. In dry degeneration, surveillance focuses on identifying new atrophy, pigmentary change, or conversion to the exudative form. Long-term management therefore combines treatment, imaging, and reassessment to match therapy with the current biology of the disease.
Factors That Influence Treatment Choices
Treatment selection depends first on whether the macular degeneration is dry or wet. This distinction matters because the underlying pathology differs. Dry disease reflects slow degenerative change in retinal support structures and photoreceptors, so treatment aims to slow cellular decline. Wet disease involves pathologic neovascularization, so treatment is directed at suppressing VEGF and sealing leaking vessels.
Stage and severity are also important. Early dry disease may require only monitoring, because the rate of progression can be slow and there may be no established benefit from aggressive intervention. Intermediate dry disease with drusen and pigment changes may prompt nutrient-based therapy because the risk of advancing to severe vision loss is higher. Advanced dry disease with geographic atrophy currently has limited treatment options, though newer agents may slow expansion in selected patients.
Age and overall health influence how treatment is delivered, especially for repeated intravitreal injections or procedures. Older individuals may have coexisting ocular disease such as cataract, glaucoma, or diabetic retinopathy, which can affect visual outcomes and procedural risk. Systemic health can also matter if a patient has a history of stroke, clotting disorders, or poor tolerance of repeated visits. These factors do not change the retinal biology itself, but they affect the practicality and risk profile of available therapies.
Previous response to treatment is another major determinant. Wet macular degeneration that responds well to one anti-VEGF agent may continue on that regimen, while persistent fluid may lead to dose changes or a different medication with stronger binding or longer duration. If scarring has already replaced active leakage, treatment may stabilize remaining tissue but cannot restore the damaged foveal architecture. In that setting, the objective shifts from improvement to preservation.
Potential Risks or Limitations of Treatment
Each treatment has limitations that arise from either the biology of the disease or the nature of the intervention. Nutritional supplements for dry macular degeneration can slow progression in selected patients, but they do not reverse drusen, regenerate lost photoreceptors, or cure atrophy. Their effect is statistical rather than immediate, and benefit depends on disease stage. They also carry some risk, such as zinc-related gastrointestinal effects or interactions with other health conditions, because they alter systemic micronutrient exposure rather than acting only in the eye.
Anti-VEGF therapy is highly effective for wet macular degeneration, but it is not a definitive cure because VEGF signaling can recur. The need for repeated injections reflects ongoing disease biology. Risks include infection inside the eye, retinal injury, transient pressure elevation, and rare bleeding or inflammation. These complications arise because the procedure introduces a needle into the globe and because repeated manipulation of a sensitive tissue carries cumulative procedural risk.
Laser photocoagulation can permanently destroy treated retina, which limits its use near the fovea. The tradeoff is biologic precision versus structural preservation. Photodynamic therapy may cause local vascular closure, but it can also injure surrounding tissues and is not appropriate for all lesion types. Complement inhibitors for geographic atrophy are promising but have limitations because they slow, rather than stop, degeneration, and they may not improve vision once central photoreceptors are lost.
More broadly, the main limitation across all macular degeneration treatments is that once the macula has sustained extensive structural damage, especially scarring or geographic atrophy, lost central vision is difficult to restore. Treatment is most effective when applied before irreversible tissue remodeling has occurred.
Conclusion
Macular degeneration is treated according to the biology of the disease subtype. Dry macular degeneration is managed mainly with antioxidant-based supplementation in selected patients, risk-factor control, and close monitoring, with newer therapies emerging for geographic atrophy. Wet macular degeneration is treated primarily with intravitreal anti-VEGF medication, which directly suppresses abnormal vessel growth and leakage, and in selected cases with laser-based or photodynamic procedures that close abnormal vessels. Supportive management and long-term surveillance help detect progression and preserve function. Across all treatment strategies, the central aim is to modify the retinal processes that drive macular injury, slow structural decline, and protect remaining central vision for as long as possible.